enGene Therapeutics Inc. Warrants (ENGNW)
Stock · NASDAQ · Health Care
$0.17as of 10/16/2026
Price chart
Active signals
High Beta21.7%
Resistance level
$0.222225
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About ENGNW
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was former…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 81
Fundamentals
- 1-day range
- $0.1338$0.1739
- Market cap
- $33.75M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 1.33
- Avg. volume
- —
52-week range
$0.1113$4.2
enGene Therapeutics Inc. Warrants Competitors
Chosen by industry and closest market cap.
- ENGNWenGene Therapeutics Inc. Warrants$0.17▲ 1.19%Market cap $33.75MP/E —$0.1113$4.2
- ALGSAligos Therapeutics Inc. Common Stock$4.86▼ 9.83%Market cap $34.10MP/E —$3.98$13.69
- ESLAEstrella Immunopharma Inc. Common Stock$0.43▼ 19.63%Market cap $32.10MP/E —$0.295$3.15
- DYAIDyadic International Inc. Common Stock$0.41▼ 2.38%Market cap $37.17MP/E —$0.3401$1.6
- QNCXQuince Therapeutics Inc. Common Stock$32.03▼ 3.61%Market cap $30.04MP/E —$15.1$910
- ELUTElutia Inc. Class A Common Stock$0.794▲ 0.63%Market cap $38.95MP/E 0.67$0.5$1.39
- CVMCel-Sci Corporation Common Stock$1.79▲ 2.87%Market cap $28.14MP/E —$0.89$10.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ENGNW enGene Therapeutics Inc. Warrants | $33.75M | — | $0.17 | ▲ 1.19% | $0.1113$4.2 |
| ALGS Aligos Therapeutics Inc. Common Stock | $34.10M | — | $4.86 | ▼ 9.83% | $3.98$13.69 |
| ESLA Estrella Immunopharma Inc. Common Stock | $32.10M | — | $0.43 | ▼ 19.63% | $0.295$3.15 |
| DYAI Dyadic International Inc. Common Stock | $37.17M | — | $0.41 | ▼ 2.38% | $0.3401$1.6 |
| QNCX Quince Therapeutics Inc. Common Stock | $30.04M | — | $32.03 | ▼ 3.61% | $15.1$910 |
| ELUT Elutia Inc. Class A Common Stock | $38.95M | 0.67 | $0.794 | ▲ 0.63% | $0.5$1.39 |
| CVM Cel-Sci Corporation Common Stock | $28.14M | — | $1.79 | ▲ 2.87% | $0.89$10.24 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
enGene Therapeutics to Host KOL Webinar on October 15, 2026
enGene Therapeutics announced it will host a Key Opinion Leader webinar on October 15, 2026. This event is expected to provide updates on the company's therapeutic developments. The warrant is currently trading near its 52-week low, reflecting high volatility and low liquidity typical for such instruments.
enGene Therapeutics to Host KOL Webinar on October 15, 2026. enGene Therapeutics announced it will host a Key Opinion Leader webinar on October 15, 2026. This event is expected to provide updates on the company's therapeutic developments. The warrant is currently trading near its 52-week low, reflecting high volatility and low liquidity typical for such instruments.